ArticleSLAS discovery : advancing life sciences R & D2021

CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target.

Tomas Friman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.